FdaApplication
NDA 209899
Identifiers
- fda_app_no: NDA209899
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2020-03-25 |
Revenue by product
ZEPOSIA
| Period | Revenue |
|---|---|
| Q2 2026 | $169.0M |
| Q1 2026 | $118.0M |
| Q4 2025 | $159.0M |
| Q3 2025 | $161.0M |
| Q2 2025 | $150.0M |
| Q1 2025 | $107.0M |
| Q4 2024 | $158.0M |
| Q3 2024 | $147.0M |
| Q2 2024 | $151.0M |
| Q1 2024 | $110.0M |
| Q4 2023 | $133.0M |
| Q3 2023 | $123.0M |
| Q2 2023 | $100.0M |
| Q1 2023 | $78.0M |
| Q4 2022 | $79.0M |
| Q3 2022 | $69.0M |
| Q2 2022 | $66.0M |
| Q1 2022 | $36.0M |
| Q4 2021 | $48.0M |
| Q3 2021 | $40.0M |
| Q2 2021 | $28.0M |
| Q1 2021 | $18.0M |
| Q4 2020 | $9.0M |
| Q3 2020 | $2.0M |
| Q2 2020 | $1.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | EQ 0.23MG BASE | CAPSULE;ORAL |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | EQ 0.92MG BASE | CAPSULE;ORAL |
| ZEPOSIA | OZANIMOD HYDROCHLORIDE | EQ 0.46MG BASE | CAPSULE;ORAL |
3 products